The evolving role of lenalidomide in the treatment of hematologic malignancies

Bibliography

• JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56:106-130.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, MALCOVATI L: Myelodysplastic syndromes-coping with ineffective hematopoiesis. N. Engl. J. Med. (2005) 352:536-538.
   PubMed Web of Science ®Google Scholar
• KYLE RA, RAJKUMAR SV: Multiple myeloma. N. Engl. J. Med. (2004) 351:1860-1873.
   PubMed Web of Science ®Google Scholar
• ALESSANDRINO EP, AMADORI S, BAROSI G et al.: Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 87:1286-1306.
   PubMed Web of Science ®Google Scholar
• LIST A, KURTIN S, ROE DJ et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. (2005) 352:549-557.
   PubMed Web of Science ®Google Scholar
• MONTSERRAT E, MORENO C, ESTEVE J, URBANO-ISPIZUA A, GINE E, BOSCH F: How I treat refractory CLL. Blood (2006) 107:1276-1283.
   PubMed Web of Science ®Google Scholar
• SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341:1565-1571.
   PubMed Web of Science ®Google Scholar
• ANDERSON KC: Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin. Hematol (2005) 42: S3-S8.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, CHAUHAN D, SHIMA Y et al.: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 96:2943-2950.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, SCHLOSSMAN RL, WELLER E et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 100:3063-3067.
   PubMed Web of Science ®Google Scholar
• HARRIS NL, JAFFE ES, DIEBOLD J et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisery Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. (1999) 17:3835-3849.
   PubMed Web of Science ®Google Scholar
• MITSIADES CS, MITSIADES N: CC-5013 (Celgene). Curr. Opin. Investig. Drugs (2004) 5:635-647.
   PubMedGoogle Scholar
• TEO S, OLIVER J, HARDEN D, STIRLING D, THOMAS S, SCHEFFLER M: A Phase I, single blind, placebo-controlled, ascending single oral dose, safety, tolerability and pharmakokinetic study of CDC-501, a novel immunomodullatory-oncologic agent, in health male subjects with a comparison of fed and fasted. Clin. Pharm. Ther. (2002) 71(2):Abstr. WP.III-64.
   Google Scholar
• MOREIRA AL, SAMPAIO EP, ZMUIDZINAS A, FRINDT P, SMITH KA, KAPLAN G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. (1993) 177:1675-1680.
   PubMed Web of Science ®Google Scholar
• CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. (1999) 163:380-386.
   PubMed Web of Science ®Google Scholar
• PAYVANDI F, WU L, HALEY M et al.: Immunomodulatory drugs inhibit expression of COX-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. (2004) 230:81-88.
   PubMed Web of Science ®Google Scholar
• NOGUEIRA AC, NEUBERT R, HELGE H, NEUBERT D: Thalidomide and the immune system. 3. Simultaneous up- and downregulation of different integrin receptors on human white blood cells. Life Sci. (1994) 55:77-92.
   PubMed Web of Science ®Google Scholar
• GUPTA D, TREON SP, SHIMA Y et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukaemia (2001) 15:1950-1961.
   PubMed Web of Science ®Google Scholar
• BARTLETT JB, DREDGE K, DALGLEISH AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer (2004) 4:314-322.
   PubMed Web of Science ®Google Scholar
• HASLETT PA, CORRAL LG, ALBERT M, KAPLAN G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. (1998) 187:1885-1892.
   PubMed Web of Science ®Google Scholar
• LEBLANC R, HIDESHIMA T, CATLEY LP et al.: Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood (2004) 103:1787-1790.
   PubMed Web of Science ®Google Scholar
• DAVIES FE, RAJE N, HIDESHIMA T et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 98:210-216.
   PubMed Web of Science ®Google Scholar
• TAI YT, LI XF, CATLEY L et al.: Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. (2005) 65:11712-11720.
   PubMed Web of Science ®Google Scholar
• STIRLING D: Thalidomide: a novel template for anticancer drugs. Semin. Oncol. (2001) 28:602-606.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ-ILIZALITURRI FJ, REDDY N, HOLKOVA B, OTTMAN E, CZUCZMAN MS: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin. Cancer Res. (2005) 11:5984-5992.
   PubMed Web of Science ®Google Scholar
• CATLEY L, WEISBERG E, TAI YT et al.: NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood (2003) 102:2615-2622.
   PubMed Web of Science ®Google Scholar
• LENTZSCH S, LEBLANC R, PODAR K et al.: Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukaemia (2003) 17:41-44.
   PubMed Web of Science ®Google Scholar
• DREDGE K, MARRIOTT JB, MACDONALD CD et al.: Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects. Br. J. Cancer (2002) 87:1166-1172.
   PubMed Web of Science ®Google Scholar
• ZHANG L-H, LU L, WU L et al.: Comparison of anti-angiogenic activities of thalidomide and lenalidomide in vitro. Blood (2005) 106:3959.
   Google Scholar
• VACCA A, SCAVELLI C, MONTEFUSCO V et al.: Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J. Clin. Oncol. (2005) 23:5334-5346.
   PubMed Web of Science ®Google Scholar
• YABU T, TOMIMOTO H, TAGUCHI Y, YAMAOKA S, IGARASHI Y, OKAZAKI T: Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood (2005) 106:125-134.
   PubMed Web of Science ®Google Scholar
• DREDGE K, HORSFALL R, ROBINSON SP et al: Orally administered lenalidomide (CC-5013) is antiangiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. (2005) 69:56-63.
   PubMed Web of Science ®Google Scholar
• PRUNERI G, BERTOLINI F, SOLIGO D et al.: Angiogenesis in myelodysplastic syndromes. Br. J. Cancer (1999) 81:1398-1401.
   PubMed Web of Science ®Google Scholar
• BELLAMY WT, RICHTER L, SIRJANI D et al.: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukaemia progenitor formation in myelodysplastic syndromes. Blood (2001) 97:1427-1434.
   PubMed Web of Science ®Google Scholar
• COULTAS L, CHAWENGSAKSOPHAK K, ROSSANT J: Endothelial cells and VEGF in vascular development. Nature (2005) 438:937-945.
   PubMed Web of Science ®Google Scholar
• MUSTO P: Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk. Res. (2004) 28:325-332.
   PubMed Web of Science ®Google Scholar
• DE PARSEVAL LM, BRADY H, VERHELLE D et al.: Lenalidomide and novel immunomodulatory drugs (IMiDs(R)): a new approach to the regulation of erythropoiesis and hemoglobin synthesis in anemia. Blood (2005) 106:2702.
   Google Scholar
• LIST A, DEWALD G, BENNETT J et al.: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. (2006) 355:1456-1465.
   PubMed Web of Science ®Google Scholar
• RAZA A, MEYER P, DUTT D et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood (2001) 98:958-965.
   PubMed Web of Science ®Google Scholar
• GANDHI AK, KANG J, NAZIRUDDIN S, PARTON A, SCHAFER PH, STIRLING DI: Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk. Res. (2006) 30:849-858.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, POULAKI V et al.: Apoptotic signalling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 99:4525-4530.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, ANDERSON KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer (2002) 2:927-937.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348:2609-2617.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, SONNEVELD P, SCHUSTER MW et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. (2005) 352:2487-2498.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, BLOOD E, VESOLE D, FONSECA R, GREIPP PR: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. (2006) 24:431-436.
   PubMed Web of Science ®Google Scholar
• ZANGARI MT G ZELDIS J et al.: Results of a Phase I study of CC-5013 for the treatment of Multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood (2001) 98:3226a (Abstr.).
   Google Scholar
• RICHARDSON PG, BLOOD E, MITSIADES CS et al.: A randomized Phase II study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 108(10):3458-3464.
   PubMed Web of Science ®Google Scholar
• BARLOGIE B: Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin. Hematol. (2003) 40:33-38.
   PubMed Web of Science ®Google Scholar
• BAZ R, WALKER E, KARAM MA et al.: Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann. Oncol. (2006) 17(12):1766-1771.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS MA, SPENCER A, ATTAL M et al.: Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a Phase III study (MM-010). Blood (2005) 106:6.
   Web of Science ®Google Scholar
• WEBER DM, CHEN C, NIESVIZKY R et al.: Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American Phase III study (MM-009). J Clin Oncol (Meeting Abstracts) (2006) 24:7521.
   Google Scholar
• RAJKUMAR SV, HAYMAN SR, LACY MQ et al.: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 106:4050-4053.
   PubMed Web of Science ®Google Scholar
• WEBER D, RANKIN K, GAVINO M, DELASALLE K, ALEXANIAN R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. (2003) 21:16-19.
   PubMed Web of Science ®Google Scholar
• PALUMBO A, FALCO P, BENEVOLO G et al.: Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. J. Clin. Oncol. (Meeting Abstracts) (2006) 24:7518.
   Google Scholar
• NIESVIZKY R, JAYABALAN DS, FURST JR et al.: Clarithromycin, lenalidomide and dexamethasone combination therapy as primary treatment of multiple myeloma. J. Clin. Oncol. (Meeting Abstracts) (2006) 24:7545.
   Google Scholar
• GERTZ MA, LACY MQ, DISPENZIERI A, HAYMAN SR: Amyloidosis. Best. Pract. Res. Clin. Haematol. (2005) 18:709-727.
   PubMed Web of Science ®Google Scholar
• DISPENZIERI A, LACY MQ, RAJKUMAR SV et al.: Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid (2003) 10:257-261.
   PubMed Web of Science ®Google Scholar
• PALLADINI G, PERFETTI V, PERLINI S et al.: The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood (2005) 105:2949-2951.
   PubMed Web of Science ®Google Scholar
• SELDIN DC, CHOUFANI EB, DEMBER LM et al.: Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin. Lymphoma (2003) 3:241-246.
   PubMedGoogle Scholar
• SANCHORAWALA V, WRIGHT DG, ROSENZWEIG M et al.: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a Phase II trial. Blood (2007) 109(2):492-496.
   PubMed Web of Science ®Google Scholar
• DISPENZIERI A, LACY MQ, ZELDENRUST SR et al.: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood (2007) 109(2):465-470.
   PubMed Web of Science ®Google Scholar
• BENNETT JM, CATOVSKY D, DANIEL MT et al.: Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. (1982) 51:189-199.
   PubMed Web of Science ®Google Scholar
• GREENBERG P, COX C, LEBEAU MM et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 89:2079-2088.
   PubMed Web of Science ®Google Scholar
• LIST AF, BENNETT J, GIAGOUNADIS A et al.: Results of the myelodysplastic syndrome-002 and -003 international Phase II studies evaluating lenalidomide (CC-(5013) Revlimid) in the treatment of transfusion-dependent patients with myelodysplastic syndrome. Haematologica (2005) 90:Abstr. 307.
   Google Scholar
• ROZMAN C, MONTSERRAT E: Chronic lymphocytic leukaemia. N Engl J Med. (1995) 333:1052-1057.
   PubMed Web of Science ®Google Scholar
• CHIORAZZI N, RAI KR, FERRARINI M: Chronic lymphocytic leukaemia. N. Engl. J. Med. (2005) 352:804-815.
   PubMed Web of Science ®Google Scholar
• CHANAN-KHAN AA, MILLER KC, DIMICELI L et al.: Results of Phase II study of lenalidomide (L) {Revlimid(R)} in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). Blood (2005) 106:447.
   PubMed Web of Science ®Google Scholar
• MUSIAL L, MILLER K, DEPAOLO D, SWINNICH D, CHANAN-KHAN AA: Prednisone (P) prophylaxis decreases incidence and severity of lenalidomide (L) induced flare reaction (flr) in patients with relapse (rel) or refractory (ref) chronic lymphocytic leukaemia. J. Clin. Oncol. (Meeting Abstracts) (2006) 24:18512.
   Google Scholar
• TEFFERI A: Myelofibrosis with myeloid metaplasia. N. Engl. J. Med. (2000) 342:1255-1265.
   PubMed Web of Science ®Google Scholar
• TEFFERI A: New insights into the pathogenesis and drug treatment of myelofibrosis. Curr. Opin. Hematol. (2006) 13:87-92.
   PubMedGoogle Scholar
• TEFFERI A: Pathogenesis of myelofibrosis with myeloid metaplasia. J. Clin. Oncol. (2005) 23:8520-8530.
   PubMed Web of Science ®Google Scholar
• JONES AV, KREIL S, ZOI K et al.: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood (2005) 106:2162-2168.
   PubMed Web of Science ®Google Scholar
• MESA RA, STEENSMA DP, PARDANANI A et al.: A Phase II trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood (2003) 101:2534-2541.
   PubMed Web of Science ®Google Scholar
• TEFFERI A, CORTES J, VERSTOVSEK S et al.: Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood (2006) 108:1158-1164.
   PubMed Web of Science ®Google Scholar
• ZONDER JA, BARLOGIE B, DURIE BG, MCCOY J, CROWLEY J, HUSSEIN MA: Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood (2006) 108: 403; author reply 404.
   PubMedGoogle Scholar
• BAZ R, WALKER E, KARAM M et al.: Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann. Oncol. (2006) 17:1766-1771.
   PubMed Web of Science ®Google Scholar
• SANCHORAWALA V, WRIGHT DG, ROSENZWEIG M et al.: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a Phase II trial. Blood (2007) 109:492-496.
   PubMed Web of Science ®Google Scholar
• DISPENZIERI A, LACY MQ, ZELDENRUST SR et al.: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood (2007) 109:465-470.
   PubMed Web of Science ®Google Scholar
• CHANAN-KHAN A, MILLER KC, MUSIAL L et al.: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukaemia: results of a Phase II study. J. Clin. Oncol. (2006) 24:5343-5349.
   PubMed Web of Science ®Google Scholar
• MILLER K, CZUCZMAN MS, DIMICELI L et al.: Lenalidomide (L) induces high response rates with molecular remission in patients (patients) with relapsed (rel) or refractory (ref) chronic lymphocytic leukaemia (CLL). J. Clin. Oncol. (Meeting Abstracts) (2006) 24:6517.
   Google Scholar